Weak guidance may hit Sun Pharma in FY26
Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India’s largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday due to a muted guidance. Image used for representation purpose only.